Sinopharm Group Co (HK:1099) has released an update.
Sinopharm Group Co. reports a slight revenue increase of 2.65% for Sinopharm Accord, reaching over 18.68 billion RMB in the third quarter of 2024, while net profit saw a decline of over 10% compared to the previous year. Despite a rise in total assets by 9.27%, net cash flow from operating activities decreased by 12.58%, reflecting ongoing financial challenges. This performance highlights the contrasting trends within the company’s financial landscape, drawing attention from investors monitoring market dynamics.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.
